This article (1) has been retracted at the request of the editors. Following institutional review by the Ohio State University it was determined that Fig. 4A and B were intentionally falsified by Dr. Ching-Shih Chen. The authors regret any inconveniences or challenges resulting from the publication and subsequent retraction of this article.
A copy of this Retraction Notice was sent to the last known email addresses for the authors. Three authors (S.K. Kulp, R.W. Brueggemeier, and C.L. Shapiro) agreed to the retraction; the four remaining authors (S-C. Weng, Y. Kashida, D. Wang, and C-S. Chen) could not be located.
References
1.
Weng
S-C
, Kashida
Y
, Kulp
SK
, Wang
D
, Brueggemeier
RW
, Shapiro
CL
, et al Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor
. Mol Cancer Ther
2008
;7
:800
–8
.©2019 American Association for Cancer Research.
2019
American Association for Cancer Research.